Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

23 juin 2021 00h00 HE | Source: Tessa Therapeutics Ltd

Tessa Therapeutics Announces Collaboration with A*STAR’s Institute of Molecular and Cell Biology to Form Cell Therapy Laboratory

BEDMINSTER, N.J. and SINGAPORE, June 23, 2021 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for...
14 mai 2021 06h00 HE | Source: Tessa Therapeutics Ltd

Tessa Therapeutics Announces Positive, Topline Data from Ongoing Phase 1 Trial of Allogeneic, “Off-the-Shelf” Cell Therapy, in Patients with Relapsed or Refractory CD30-Positive Lymphoma

BEDMINSTER, N.J. and SINGAPORE, May 14, 2021 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological...
07 mai 2021 06h00 HE | Source: Tessa Therapeutics Ltd

Tessa Therapeutics’ Allogeneic, “Off-the-Shelf” CD30 Cell Therapy to be Featured in Podium Presentation at the ASGCT 24th Annual Meeting

BEDMINSTER, N.J. and SINGAPORE, May 07, 2021 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological...
30 avr. 2021 06h00 HE | Source: Tessa Therapeutics Ltd

Tessa Therapeutics Announces Enrollment of 12 Patient Pilot Cohort in its Relapsed or Refractory Hodgkin Lymphoma Phase 2 Study

82 Patient Pivotal cohort expected to commence in second half of 2021 BEDMINSTER, N.J. and SINGAPORE, April 30, 2021 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell...

Page précédente